Targeting tumor vasculature represents an interesting approach for the treatment of solid tumors. The avb3 integrins have been found to be specifically associated with angiogenesis in tumors. By using bacteriophage display technology, Ruoslahti et al found that a group of peptides containing the RGD (Arg-Gly-Asp) motif have high-binding affinity to the avb3 integrins in tumors. In this study, we designed a fusion protein containing the RGD sequence and the Fc fragment of mouse IgG in order to target the Fc portion of IgG to the tumor vasculature to elicit an antiangiogenesis immune response. In vivo angiogenesis and tumor studies demonstrated that the fusion protein (RGD/mFc) inhibited tumor angiogenesis and tumor growth and improved overall survival. This approach may generate new therapeutic agents for solid tumor treatment.
N ew blood vessel growth (angiogenesis) is required for continued tumor growth. [1] [2] [3] Therefore, tumor vasculature has become a prime target for cancer therapy because of its essential role in the growth and survival of all solid tumors. 4 One way to target the tumor vasculature is to inhibit the growth of new blood vessels in tumors by using antiangiogenic reagents such as angiostatin and endostatin. 5, 6 A different way to target tumor vasculature involves vasculature-specific targeting. The avb3 integrins have been found to be tumor specific, and therefore, excellent tumor targets 7 . Specific antibodies against the avb3 integrins have been developed 8, 9 and used to target tumors with immunotoxins. 10 Recently, another approach using bacteriophage display technology found a group of peptides containing the Arg-Gly-Asp (RGD) motif that has a high affinity for avb3 integrins and is capable of homing to tumors. 11, 12 These peptides have the potential to allow targeting of tumor neovasculature with toxins such as proapoptotic peptides. 13 The Fc fragment of IgG is responsible for immune responses induced by antibodies.
14 First, the Fc fragment can trigger phagocytosis by neutrophils or macrophages because these cells express Fc receptors. Second, the Fc fragment is able to activate natural killer cells to lyse the cells bearing the Fc receptor. 15 Third, and more importantly, it is the Fc portion of IgG that triggers the cascade of the complement system by binding to the C1q protein. Therefore, the Fc fragment of IgG has been utilized as a functional motif in tumor inhibition by fusing it with other targeting proteins such as tissue factors. 15, 16 In the present study, we designed a fusion protein containing an RGD peptide (ACDCRGDCFCG) and the Fc fragment of mouse IgG. In order to have this fusion protein expressed in a secreted form, a signal peptide sequence was inserted before the RGD peptide sequence in the vector. We expected that the fusion protein will bind to avb3 integrins of the tumor vasculature and the Fc portion will then activate immune responses including the complement system, NK cells, neutrophils and/or macrophages to destroy the endothelial cells of blood vessels in tumors and tumor cells that express avb3 integrins. The experimental results demonstrated that when the fusion protein is expressed by tumor cells it is indeed able to inhibit tumor angiogenesis and tumor growth. BRL, Grand Island, NY) containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT) and 50 mg/ml of gentamycin (GIBCO BRL). Murine tumor cells, TC-1, which was derived from primary epithelial cells of C57BL/ 6 mice cotransformed with HPV-16 E6 and E7 and c-Haras oncogenes (a kind gift from Dr TC Wu, John Hopkins University), were cultured in RPMI 1640 medium containing 10% FBS, 0.2 mM nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 50 mg/ml gentamycin at 371C with 5% CO 2 . AD-293 cells (Stratagene, La Jolla, CA #240085) were cultured in DME medium containing 10% heat-inactivated horse serum, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 1.5 g/l sodium bicarbonate, and 50 mg/ml gentamycin at 371C with 5% CO 2 . Human prostate tumor cells, DU-145 (ATCC #HTB-81) were cultured in EME medium containing 10% FBS, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 1.5 g/l sodium bicarbonate, and 50 mg/ml gentamycin at 371C with 5% CO 2 .
Construction of the RGD/mFc fusion protein vector and transfection
A pair of primers was designed to amplify the Fc fragment (from the hinge region to the end of the cDNA, 741 bp) of mouse IgG cDNA sequence (ATCC #MGC-6628): 5 0 primer CCAAGCTTGCCTGCGACTGCCGA GGAGATTGTTTCTGCGGCGACAAGAAAATTGT GCCCAGGGATTGTGGTTGTAAGCCTTGC; 3 0 primer CGGGATCCCGTTTACCAGGAGAGTGGGAGAG. At the 5 0 end of the upstream primer, after a Hind III enzyme site, a sequence encoding ACDCRGDCFCG peptide was added. A BamHI enzyme site was added to the 5 0 end of the downstream primer. The PCR product was then inserted into the expression vector pSecTag2B (Invitrogen, Carlsbad, CA), in frame, after the signal peptide sequence. The full sequence was confirmed by sequencing. The generated vector, pRGD/ mFc, was then transfected into B16F0 tumor cells using the Lipofectamine transfection reagent according to the manufacturer's protocol (Gibco BRL). Stable cell lines were selected as single clones in DME medium containing 200 mg/ml Zeocin (Sigma, St Louis, MO) for 3-4 weeks. Vector pSecTag2B was transfected into B16F0 cells as well and a stable cell line was selected as B16F0/mock.
Western blot and FACS analysis
A total of 5 Â 10 6 B16F0/mock cells and RGD/mFcexpressing B16F0 cells were cultured in 10 ml of culture medium for 2 days. The 10 ml supernatant was then collected and concentrated through Millipore's Microcon to 1 ml. From each sample, 30 ml of protein solution was run on SDS-PAGE gel. An amount of 0.2 mg of purified mouse IgG was loaded in one well as positive control. The fusion protein was detected by using anti-Fc fragment antibody (Bethyl Laboratories, Montgomery, TX) with the Super Signal West Pico Chemiluminescent detection kit (Pierce, Rockford, IL). Stable cell lines that express RGD/mFc were also analyzed by intracellular fluorescence activated cell sorting (FACS). Briefly, the secretion of the protein was blocked and the cells were permeabilized with a Cytofix/Cytoperm Plus Kit (BD PharMingen, San Diego, CA). The cells were then stained with FITCconjugated anti-mouse Fc antibody and analyzed using a FACS Calibur (BD Biosciences, San Jose, CA).
Matrigel plug and immunohistochemical analyses
A total of 5 Â 10 5 RGD/mFc-expressing B16F0 cells or mock-transfected cells were mixed with 0.2 ml of liquid Matrigel (BD Biosciences) and injected intradermally into female C57BL/6J mice. In order to visualize the blood vessels within the tumors, at day 8 the mice were intravenously injected with 50 mg/mouse of FITC labeled Lectin to visualize blood vessels (Sigma, St Louis, MO). After 30 Minutes, the Matrigel plugs containing tumor cells were isolated. After a quick observation under a fluorescent microscope, the plugs were frozen for sectioning. Thick sections (20 mm) were made and observed using fluorescent microscopy. For immunohistochemical analysis, 5 Â 10 5 RGD/mFc-expressing B16F0 cells or mock-transfected B16F0 cells in 0.2 ml of 1x PBS were intradermally injected into C57BL/6J mice. After 14 days, the tumors were excised and frozen sections (5 mm) were made. The slides were then fixed and immnuohistochemically stained with anti-CD31 antibody and visualized with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). The microvascular density was counted and presented as the number of vessels per square millimeter.
Adenovirus vector construction to express RGD/mFc
A recombinant adenoviral vector containing the coding sequence for the RGD/mFc fusion protein was constructed by using the AdEasy Adenoviral Vector System (Stratagene, La Jolla, CA). Briefly, the RGD/mFc sequence was amplified from the pRGD/mFc and cloned into the pShuttle-CMV vector; the resulting pShuttle-CMV/RGD/mFc was then transformed into BJ5183-AD-1 electorporation competent cells to generate recombinant adenoviral vector pAd-RGD/mFc. Following Pac I digestion to linearize the pAd-RGD/mFc viral vector, it was transfected into AD-293 cells by using the Transfection MBS Mammalian Transfection Kit (Stratagene). After 10 days, primary viral stocks were prepared from the transfected cells and viral titer determined with BD Biosciences' Adeno-X Rapid Titer Kit. Amplification of recombinant virus was performed by infecting 125 Â 10 6 AD-293 cells at an MOI of 3 for about 4 days until cytopathic effects were complete. Finally, the recombinant virus was harvested and purified by using BD Biosciences' Adeno-X Virus Purification Kits according to the instructions provided. The purified virus was then titered, aliquoted, and stored at À801C for future use. Production of RGD/mFc fusion protein was confirmed by Western blot from different cells (AD-293 cells, TC-1 cells, etc) infected with AD/RGD/mFc. AD-LacZ from Stratagene was amplified and titered as stated above and used as the control. . For the survival study, tumorbearing mice were monitored until death or until tumors reached the size of 20 mm in diameter at which point the mice were euthanized and considered terminated for survival. Each group consisted of eight mice. The Student's t-test was used to analyze the tumor volume data. In order to determine if RGD/mFC can inhibit tumor metastases, 5 Â 10 5 B16F0/mock or RGD/mFCexpressing B16F0 cells were intravenously injected into female C57BL/6J mice through tail vein. After 24 days, the mice were killed and the lung tumor nodules were counted.
Animal study with transfected tumor cells
Animal studies with AD-RGD/mFc TC-1 tumor cells were used in this study because of their high in vitro viral infection rate (B100% at MOI of 5). Briefly, 2 Â 10 5 TC-1 tumor cells were intradermally injected into C57BL/6J mice on both sides of the flanks. After 10 days, adenovirus particles encoding RGD/mFc (10 8 PFU/50 ml) were directly injected into the tumors on the right side. The injection was repeated four times at a 3-day interval. In the control groups, 1x PBS or adenovirus particles encoding Lac Z were injected into the tumors in the same manner.
In order to test RGD/mFc's function in human tumor cells, the human prostate tumor cell line DU-145 was used in a nude mouse model. In total, 5 Â 10 6 DU-145 cells were intradermally injected into nude mice on both sides of the flanks. After 21 days, adenovirus particles encoding RGD/mFc (10 8 PFU/50 ml) were directly injected into the tumors on the right side. The injection was repeated four times at a 3-day interval. In the control groups, 1x PBS or adenovirus particles encoding Lac Z were injected into the tumors in the same manner. Figure 1 shows a diagram of the fusion protein, RGD/ mFc. It contains an RGD peptide sequence (ACDCRGDCFCG) in the front followed by the hinge region, CH2, and CH3 regions of mouse IgG. To confirm the expression of the fusion protein, the vector pRGD/ mFc was linerarized and transfected into B16F0 melanoma cells and stable expressing cell lines were obtained. Western blot analysis showed that the protein is secreted into the culture medium (Fig 2a) . The expression level of the fusion protein is variable in different clones. Although the growth and morphology characteristics of these clones are similar compared to the parental B16F0 tumor cells, clone #15 (Fig 2a, lane 6 ) and sometime clone #17 (Fig 2a,  lane 7) were used in the following experiment because of their high level expression of the fusion protein. Intracellular FACS analysis using anti-mouse Fc fragment antibody confirmed the expression of the protein within the cells (Fig 2b) .
Results

RGD/mFc expression
RGD/mFc inhibits angiogenesis in tumor
In order to determine whether the RGD/mFc fusion protein can inhibit tumor angiogenesis, B16F0 cells genetically engineered to express RGD/mFc protein were mixed with liquid Matrigel and intradermally injected into C57BL/6J mice. After 8 days, the mice were intravenously injected with FITC labeled Lectin 30 minutes before tumor isolation. The Matrigel implants were isolated by excision and briefly observed under a fluorescent microscope. Thick sections (20 mm) were then made and observed using fluorescent microscopy. Although there are minimal blood vessels on the surface of the Matrigel alone implant (Fig 3a) , we did not see any vessels inside the implant (Fig 3b) . In contrast, B16F0/ mock tumor cells dramatically enhanced new blood vessel formation in the Matrigel implant (Figs 3c and d) . However, when the cells were genetically engineered to express RGD/mFc, the formation of new blood vessels was dramatically decreased (Figs 3e and f) , indicating that the RGD/Fc fusion protein has antiangiogenesis activity. Figures 4b-d) . In another tumor model, TC-1, similar antiangiogenesis effect were observed (data not shown).
RGD/mFc fusion protein inhibits tumor growth
In order to determine statistically whether the RGD/mFc fusion protein can inhibit tumor growth, B16F0 tumor cells expressing RGD/mFc protein were intradermally injected into female C57BL/6J mice, while B16F0/mock tumors cells were also injected into separate groups of mice as controls. The tumor volumes were measured, statistically analyzed, and plotted. As shown in Figure 5 , when the tumors were measurable, a significant size difference between tumors from B16F0/mock and tumors from RGD/mFc-expressing B16F0 was observed (at all data points, Po.001). The survival of the mice bearing RGD/mFc-expressing B16F0 tumors was also monitored. The RGD/mFc fusion protein significantly prolonged survival time of the mice. At day 45, 75% of the mice bearing cells expressing RGD/mFc were still alive, while all the controls bearing B16F0/mock cells died before day 20 (Fig 6) .
In order to further determine whether RGD/mFc as an agent has antitumor activity, an adenovirus vector encoding RGD/mFc was constructed. The vector was then transfected into AD-293 cells, from which adenovirus particles were isolated. They were then amplified, purified, and titered. After directly injecting 1x10 8 PFU of the virus into tumors (TC-1 tumor in C57BL/6J mice and DU-145 tumor in nude mice), a significant delay of tumor growth was observed in both tumor models (Figs 7 and 8 ). For TC-1 tumor cells, a significant difference between the virus injected tumors and control tumors (AD-LacZinjected tumors or PBS-injected tumors) was observed 3 days after the first virus-injection (P ¼ .017 and P ¼ .016). For DU-145 tumor cells, a significant difference between the virus-injected tumors and AD-LacZ-injected tumors was observed 3 days after the second virus injection (P ¼ .023). Furthermore, the growth of the tumors in the left flanks (uninjected) of the mice was significantly inhibited as well, compared to that of the controls.
RGD/mFc fusion protein inhibits tumor metastases
In order to determine if the RGD/mFC fusion protein can inhibits tumor metastases, two clones of RGD/mFc expressing B16F0 tumors were i.v. injected into mice through the tail vein. As controls, B16F0/mock cells were also injected in the same manner. Lung metastases measured as lung nodules 24 days after the tumor inoculation are presented as Table 1 . Both the RGD/ mFc-expressing clones generated a significantly fewer lung tumor nodules (9.62574.09 and 23.87577.98, respectively) than the control tumor cells (4200).
Discussion
In this study, a fusion protein (RGD/mFc) containing an RGD motif and the Fc fragment of mouse IgG (Fig 1) was created and expressed by tumor cells through transfection or adenovirus-mediated transduction. The protein's identity was confirmed by Western blotting analysis and flow cytometric analysis (Fig 2) .
The first experiment we performed to test RGD/mFc's function is a Matrigel plug assay, in which RGD/mFcexpressing B16F0 tumor cells were mixed with liquid 
RGD/mFc inhibits tumor angiogenesis J Li et al
Matrigel and subcutaneously injected into mice. As Figure 3 shows, in the tumors formed from RGD/mFcexpressing B16F0 tumor cells, the blood vessels are dramatically decreased compared to the control tumors. The anti-blood vessel formation effect of RGD/mFc was further confirmed by immunohistochemical staining of the tumor sections using anti-CD31 antibody (Fig 4) . Tumor cells expressing RGD/mFc grew significantly slower in vivo compared to mock-transfected cells B16F0/mock. The mice bearing tumors expressing RGD/mFc lived significantly longer than mice bearing B16F0/mock tumors ( Figs 5 and 6) . The difference is clearly due to the expression of RGD/mFc that activated antitumor immune responses, since tumor cells expressing RGD/mFc and B16F0/mock showed similar growth rate and morphological characteristics in vitro (data not shown).
To test RGD/mFc's antitumor growth effect as an agent, an adenovirus vector encoding RGD/mFc fusion protein was constructed and transfected into AD-293 cells, from which adenovirus particles were isolated. These replication-deficient virus particles were directly injected into tumors. The results demonstrated that RGD/mFc expressed by the virus-infected cells inhibits tumor growth in both murine and human tumors. More importantly, the expressed fusion protein enters the circulation system and reaches distant tumors and inhibits their growth (Fig 7) with no obvious adverse effects. It is impossible to deliver genes or proteins directly into all tumors in humans; therefore, newly developed antitumor agents must be delivered systemically and be able to reach distant tumors.
As previously discussed, the Fc fragment of immunoglobulin G (IgG) is responsible for immune responses induced by antibodies.
14 First, the Fc fragment can trigger compared to controls, indicating that the antitumor effect was achieved by either the complement system or natural killer cells or both. Surprisingly, the inhibition effect of RGD/mFc on distant tumors is almost as effective as the injected tumor in the nude mice model; while in the TC-1 tumor model, the distant tumors were inhibited but not as effective as the injected tumor. The antiangiogenesis effect of RGD/mFc may vary in different types of cells, especially when the tumor cells are from different species. It is possible that they may express the target molecules, avb3 at different levels and the in vivo transduction efficiency may be different as well. Further studies are needed to clarify these issues.
In conclusion, targeting of the immune functional unit using RGD peptide is feasible. Recent studies have demonstrated that not only new vasculature endothelial cells but also most of tumor cells express avb3 integrins. 11 Therefore, the RGD/mFc fusion protein should target both new blood vessels and existing tumor cells. As a result, this fusion protein may represent an agent that could eradicate tumors in addition to inhibiting tumor growth. In addition to the gene therapy methods, we are also currently producing RGD/mFc fusion proteins in large scale using bacterium fermentation technology as another option. The recombinant protein will be tested in similar mouse models mentioned in this study. If successful, this study will quickly be moved into clinical trials. Different tumor cell lines were i.v. injected into C57BL/6J mice (5 Â 10 5 /mouse). After 24 days, the mice were killed and the tumor nodules on the lungs were counted. secretarial assistance. This work was supported in part by the Oncology Research Foundation of the Greenville Hospital System, Greenville, SC, USA
